Royalty Table

Below are the disclosed royalties Ligand currently receives or is eligible to receive based on future drug approvals. 

Disclosed Licensed Royalties

Licensee Program Annual Royalty Structure on all Sales
Amgen (1) Kyprolis 1.5% – Sales up to and including $250M
2.0% – Sales from $250M - $500M
2.5% – Sales in the range of $500M - $750M
3.0% – Sales greater than $750M
Acrotech/CASI (1) Evomela 20%
SAGE (1) Zulresso 3%
Pfizer (1) Viviant/Conbriza and Duavee 0.5% – Less than $400M
1.5% – Sales from $400M - $1.0B
2.5% – Sales greater than $1.0B
Palvella PTX-022 5.0% - 9.8%
Travere Therapeutics Sparsentan 9%
Viking TR Beta (VK2809 and VK0214) 3.5% - 7.5%
Sermonix Lasofoxifene 6.0% - 10.0%
Merck V114 Low single digit royalty
Serum Institute of India Pnuemosil Low single digit royalty
Corvus Ciforadenant Mid-single digit to low-teen
Dianomi Mineral Coated Microparticle 2.0% - 3.0%
GigaGen OmniAb-GigaGen Mid-single digit royalty
MEI Pharma ME-344 Low single digit royalty
Melinta Baxdela 2.5%
Novan SB206 7.0% - 10.0%
Nucorion Various 4.0% - 9.0%
Sedor CE-Budesonide and CE-Meloxicam 8.0% – Less than $25M
10.0% – Sales greater than $25M
Sedor CE-Fosphenytoin 11%
Seelos Various 4.0% - 10.0%
Takeda pevonedistat Low single digit royalty
Verona Ensifentrine (RPL554) Low to mid-single digit royalty
Viking DGAT-1 3.0% - 7.0%
Viking FBPase Inhibitor (VK0612) 7.5% - 9.5%
Viking Oral EPO 4.5% - 8.5%
Viking SARM (VK5211) 7.25% - 9.25%
Xi'an Xintong MB07133 6%
Xi'an Xintong Pradefovir 9%
  1. Currently receiving royalty payments